NCT02683564View on ClinicalTrials.gov

BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study

PHASE3UnknownINTERVENTIONAL
Enrollment

548

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

July 31, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

BOW015

monoclonal antibody against TNF-alpha

DRUG

Remicade

monoclonal antibody against TNF-alpha

Sponsors
All Listed Sponsors
lead

Epirus Biopharmaceuticals (Switzerland) GmbH

INDUSTRY